Palvella Therapeutics (NASDAQ:PVLA) Earns Buy Rating from Analysts at Canaccord Genuity Group
Canaccord Genuity Group assumed coverage on shares of Palvella Therapeutics (NASDAQ:PVLA – Free Report) in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $39.00 price objective on the stock. A number of other equities analysts have also recently commented on the stock. HC […]
Canaccord Genuity Group assumed coverage on shares of Palvella Therapeutics (NASDAQ:PVLA – Free Report) in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $39.00 price objective on the stock. A number of other equities analysts have also recently commented on the stock. HC […]
